Collaboration and License Agreements - Additional Information (Detail) - Janssen Pharmaceutical NV [Member] - USD ($) |
9 Months Ended | |
|---|---|---|
Sep. 30, 2021 |
Sep. 30, 2020 |
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Accrued royalties | $ 0 | $ 0 |
| Maximum [Member] | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Percentage of royalty on net sales | 8.00% |
| X | ||||||||||
- Definition Royalty percentage based on net sales. No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|